Articles tagged with Prostate Cancer
A team of scientists at Queen Mary University of London is working on a novel approach to treat prostate cancer using a modified type of flu virus. The goal is to develop a new treatment that can target and kill cancer cells while leaving non-cancer cells unharmed. By modifying the virus to deliver it via the blood, the researchers hop...
Finasteride has been shown to reduce the risk of prostate cancer by 25 percent, with no significant increase in mortality rates. The study's findings have eliminated concerns over initial reports of potential risks, and doctors are now recommending finasteride as a preventive strategy for prostate cancer.
Researchers at UIC will study mangosteen's phytochemicals and their impact on prostate cancer cells, with the goal of developing a new treatment approach. The $1.7M grant from NCI aims to investigate the unique xanthones in mangosteen that promote androgen receptor degradation.
Researchers have discovered that the GREB1 gene amplifies androgen receptor output in human prostate cancer cells, contributing to antiandrogen resistance. Inhibiting GREB1 converts high-AR output cells to low-output states, improving enzalutamide treatment effectiveness.
Researchers identified a link between BRCA2 mutations and aggressive prostate cancer in men, increasing their risk of developing other cancers. The study also found that patients with BRCA2 mutations have poorer treatment responses and outcomes.
Researchers identified genetic alterations in low-risk prostate cancers that may indicate higher-risk cancer presence, guiding men to consider treatment. The study suggests a potential test to validate these alterations, enabling personalized treatment decisions.
Recent advancements in prostate imaging modalities have significantly enhanced the diagnosis of prostate cancer. Androgen receptor-based imaging is emerging as a promising approach for non-invasive detection using non-steroidal antiandrogen agents.
A recent study published in the Journal of Clinical Oncology found that time to biochemical failure can be used as a surrogate endpoint for locally advanced prostate cancer treatment, reducing overall survival benefit by 6% compared to traditional endpoints. The analysis of NRG-RTOG 9202 clinical trial results showed significant associ...
A recent study suggests that black men diagnosed with low-risk prostate cancer (Gleason score 6) may have a more aggressive form of the disease, leading to higher mortality rates compared to non-black men. The research found a significant disparity in prostate cancer death rates between black and non-black patients with Gleason 6 cancers.
A new assay can analyze small amounts of material to estimate metastatic risk, enhancing prostate cancer evaluation. The Next-Generation Copy Number Alteration (NG-CNA) assay is a targeted amplification sequencing technique that can process samples faster and decrease the cost per sample.
A 29-year study found that only 12% of men with advanced prostate cancer were saved from dying by surgery, while 80% had died after 29 years. Surgery did extend life expectancy by 2.9 years, but also came with significant side effects.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A team of researchers has created a computer model using cancer patient data to predict the course of disease for prostate cancer. The model, currently being implemented at a clinic in Germany, can identify key mutations that trigger the disease.
A 20-year study from Northwestern Medicine found men with inflammatory bowel disease have four to five times higher risk of prostate cancer and elevated PSA values. Researchers are now investigating the mechanism behind gut inflammation leading to prostate cancer.
A new medical software system, SmartTarget, enhances prostate cancer detection by overlaying MRI scans onto ultrasound images, guiding surgeons during biopsies. The technology has shown that combining both techniques can detect clinically relevant cancers missed with current methods.
A study of 150 popular YouTube videos on prostate cancer found that 77% had factual errors or biased content, while only 53% adequately described potential harms and side effects. Researchers urge viewers to consult credible sources for accurate information on prostate cancer.
A new study has identified a novel molecular driver of lethal prostate cancer and a molecule that could be used to attack it. The findings, if confirmed in humans, could lead to more effective ways to control certain aggressive types of prostate cancer.
Researchers found that combining surgery with post-operative low-dose radiation and hormone therapy reduces prostate cancer death risk to less than 10% for men with aggressive prostate cancer. In contrast, surgery alone increases the risk of death from prostate cancer within five years.
A study led by CNIO has defined a blood-based biomarker that can determine the most effective treatment for castration-resistant prostate cancer patients. The biomarker, which analyzes the presence of a specific gene in circulating tumour DNA, shows promise for improved survival rates and personalized therapy.
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
A study of 1244 patients found a 72% higher risk of heart failure in those receiving androgen deprivation therapy compared to non-users. The researchers recommend counseling patients on modifiable heart failure risk factors and providing cardiovascular examinations.
Researchers will identify biomarkers for DNA repair defects in tumors, enabling faster decision-making on treatment choices. A clinical trial will test carboplatin therapy's effectiveness in advanced prostate cancer.
A study found that men with prostate cancer value quality of life and will trade off survival odds for fewer side effects, including urinary incontinence and impotence. The research suggests that patients may prefer less invasive treatments like focal therapy or active surveillance to reduce harm.
Researchers at the University of Notre Dame have found a way to inhibit T-cell activation by targeting nitration of an amino acid in cancer cells. This approach could enhance cancer immunotherapy by identifying activity-based markers and designing approaches that shut down specific mechanisms inhibiting T-cell activation.
A new type of molecule blocks the action of genes that drive therapy-resistant prostate cancer growth, reducing cell proliferation by 95%. The cyclic peptoids also blocked a key growth signal in live animal tests.
A large, long-term study found SBRT to be safe and effective for men with low- and intermediate-risk prostate cancer. The treatment delivered substantially larger doses of radiation per session, reducing the duration of treatment without increasing the risk of severe side effects.
The SPPORT trial found that adding pelvic lymph node treatment and short-term hormone therapy to standard treatment extends time before cancer spreads. This combination therapy resulted in higher freedom-from-progression rates and lower distant metastasis rates compared to standard treatments alone.
A new analysis of genetic data and clinical trial results suggests that African-American men may have comparatively higher cure rates when treated with radiation therapy. The study found that tumors from African-American men were more likely to have indicators of increased sensitivity to radiation, leading to improved outcomes.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
Researchers at City of Hope have developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses, eliminating difficult-to-treat prostate cancer in experimental models. The novel two-step strategy relies on two opposite actions of the same 'hot and cold' molecule to remove obstacles to treating me...
A new test developed by scientists at the University of York can accurately identify life-threatening prostate cancers, which could lead to fewer unnecessary surgeries and radiotherapies. The test has shown a high accuracy rate of up to 92%, potentially reducing healthcare costs and side effects for patients.
Recent studies conducted by CHAAMPS reveal significant health disparities among black men, including racial disparities in hospitalizations for heart failure. Additionally, the organization aims to address violent encounters between police and young black men through community-based initiatives.
The new guideline recommends moderate hypofractionation (240-340 cGy) as an alternative to conventional fractionation for men with early-stage prostate cancer. Hypofractionated radiation therapy can be completed in four to five weeks, compared to eight to nine weeks for conventional radiation.
A new study finds that baseline PSA levels measured at midlife strongly predict total and aggressive prostate cancer in black men years later. The research suggests targeted screening based on a midlife PSA might identify black men at high risk while minimizing screening in those at low risk.
Researchers are developing a robot that can detect and treat prostate cancer more accurately, reducing the need for invasive procedures. The robot will guide a steerable flexible needle to target cancer cells, while AI and mathematical modeling ensure precise placement of radioactive material.
Researchers at UCLA have discovered that late-stage prostate and lung cancers share common molecular mechanisms. The study found that these cancers can evolve similarly, even from different organs, which could lead to the development of drugs to treat not just prostate and lung cancers but also small cell cancers of almost any organ.
Researchers have discovered a potential treatment for prostate cancer using riluzole, a drug approved for ALS treatment. The study found that riluzole promotes the degradation of androgen receptors, which drives prostate cancer growth.
A new pathology test using AI can accurately predict clinically significant prostate cancer disease progression following surgery, helping guide treatment decisions. The Precise MD post-op test reclassified 58% of intermediate risk patients as low risk and 42% as high risk for significant disease progression.
A new study finds that baseline PSA levels in black men between 40 and 60 can strongly predict future development of prostate cancer and its most aggressive forms. Elevated PSA levels are associated with increased risk, even among those within the normal range.
A Phase III clinical trial is enrolling men with metastatic Stage 4 prostate cancer to compare standard systemic therapy with or without surgery or radiation therapy. The goal is to delay disease progression and improve survival.
A recent study published in the journal Cancer found that patients with locally advanced prostate cancer who received a combination of prostate removal and radiation therapy had a higher rate of survival compared to those treated with radiation alone. The study analyzed data from over 13,000 men diagnosed with high-risk prostate cancer...
A survey of over 2,500 respondents found low awareness of urological conditions, particularly among men. Men are less knowledgeable about urological symptoms than women, and many do not take early signs seriously, leading to delayed diagnosis and potentially life-threatening consequences.
Researchers developed an mRNA-based nanotherapeutic to reintroduce functional copies of PTEN into cancer cells, restoring tumor suppressor function and killing cancer cells. The therapy showed significant suppression of tumor growth and progression in mouse models of prostate cancer.
A study estimates that prostate cancer screening and treatment for older men costs Medicare over $1.2 billion annually. The majority of this cost goes towards treating low-grade disease with Gleason scores of 6, which may not significantly impact life expectancy.
A research team at the University of Turku discovered a link between HOXB13 and CIP2A genes and aggressiveness of prostate cancer. The simultaneous expression of these two gene variants predisposes men to get prostate cancer earlier in life and stimulates tumor formation.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
International experts advise against routine PSA screening for prostate cancer, citing small benefits and potential harm. However, clinicians should engage in shared decision-making with patients considering screening, especially those at higher risk of prostate cancer death.
Researchers at Cedars-Sinai Medical Center discovered how hormone therapy can cause prostate cancer to spread by transforming some cancer cells into aggressive neuroendocrine cancer-type cells. A potential simple blood test may help predict when this type of therapy resistance will occur, according to the study.
Researchers discovered a link between ANO7 gene mutations and aggressive prostate cancer risk and severity, suggesting improved diagnosis and treatment options. The study found specific genetic mutations that correlated with increased disease risk and poorer survival rates.
Heavy alcohol consumption during adolescence and young adulthood may increase the odds of developing high-grade prostate cancer. Men who drank at least seven drinks per week between ages 15-19 had three times the odds of being diagnosed with clinically significant prostate cancer compared to non-drinkers.
Blocking POM121 transport inhibits tumor aggressiveness and restores chemotherapy efficacy in preclinical models. This study identifies nuclear pore proteins as effective anti-cancer targets for advanced prostate cancers, offering a new approach to target undruggable molecular drivers.
A low-protein diet during pregnancy and lactation may increase the risk of prostate cancer in offspring, according to a study with rats. The study found that females fed a low-protein diet had offspring with preneoplastic alterations capable of interfering with glandular function.
A team of scientists has developed a faster and more accurate way to test new treatments for the most aggressive form of prostate cancer. Lab-grown tumours derived from donor patient tumours enable researchers to test drug combinations quickly and efficiently, identifying those that cause the most striking reduction in tumour growth.
A blood test can predict which treatment is most likely to extend a patient's life with advanced prostate cancer. Researchers found that patients who tested positive for the protein AR-V7 responded best to taxane-based chemotherapy, while those who tested negative responded better to hormone-targeting therapy.
A study by University of Oulu researchers has identified novel genes and mechanisms associated with aggressive prostate cancer progression. The research suggests ways to improve risk stratification and clinical treatment for advanced prostate cancer.
Scientists have identified genetic errors common in metastatic prostate tumors, including alterations in the androgen receptor region. The study found that about 80% of aggressive tumors had similar genetic changes, which could lead to new treatment options for patients with aggressive forms of prostate cancer.
A new study found that eating an early supper and having a long interval between the last meal and sleep are associated with lower breast and prostate cancer risks. Participants who had supper before 9pm or slept 2 or more hours after supper had a reduced risk of developing these cancers.
The RESPOND study, funded by $26.5 million grants, aims to understand why African-American men are at higher risk for developing aggressive forms of prostate cancer. Researchers will assess social stressors and genetics to identify genetic markers for the disease.
Researchers investigating genetic and environmental factors contributing to aggressive prostate cancer in African-American men, a population with a 15% lifetime risk compared to 10% for white men.
A new study has found that eating an early supper is associated with a lower risk of breast and prostate cancer. Participants who ate before 9pm had a 20% lower risk compared to those who ate late, suggesting the importance of meal timing in cancer prevention.